David Rabago1, Marlon Mundt2, Aleksandra Zgierska2, Jessica Grettie3. 1. Department of Family Medicine University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, United States. Electronic address: david.rabago@fammed.wisc.edu. 2. Department of Family Medicine University of Wisconsin School of Medicine and Public Health, Madison, WI 53715, United States. 3. Wisconsin Center for Education Research University of Wisconsin, Madison, WI 53706, United States.
Abstract
OBJECTIVE:Knee osteoarthritis (OA) is a common, debilitating chronic disease. Prolotherapy is an injection therapy for chronic musculoskeletal pain. Recent 52-week randomized controlled and open label studies have reported improvement of knee OA-specific outcomes compared to baseline status, and blinded saline control injections and at-home exercise therapy (p<0.05). However, long term effects of prolotherapy for knee OA are unknown. We therefore assessed long-term effects of prolotherapy on knee pain, function and stiffness among adults with knee OA. DESIGN: Post clinical-trial, open-label follow-up study. SETTING: Outpatient; adults with mild-to-severe knee OA completing a 52-week prolotherapy study were enrolled. INTERVENTION AND OUTCOME MEASURES: Participants received 3-5 monthly interventions and were assessed using the validated Western Ontario McMaster University Osteoarthritis Index, (WOMAC, 0-100 points), at baseline, 12, 26, 52 weeks, and 2.5 years. RESULTS:65 participants (58±7.4 years old, 38 female) received 4.6±0.69 injection sessions in the initial 17-week treatment period. They reported progressive improvement in WOMAC scores at all time points in excess of minimal clinical important improvement benchmarks during the initial 52-week study period, from 13.8±17.4 points (23.6%) at 12 weeks, to 20.9±2.8 points, (p<0.05; 35.8% improvement) at 2.5±0.6 years (range 1.6-3.5 years) in the current follow-up analysis. Among assessed covariates, none were predictive of improvement in the WOMAC score. CONCLUSIONS:Prolotherapy resulted in safe, significant, progressive improvement of knee pain, function and stiffness scores among most participants through a mean follow-up of 2.5 years and may be an appropriate therapy for patients with knee OA refractory to other conservative care.
RCT Entities:
OBJECTIVE:Knee osteoarthritis (OA) is a common, debilitating chronic disease. Prolotherapy is an injection therapy for chronic musculoskeletal pain. Recent 52-week randomized controlled and open label studies have reported improvement of knee OA-specific outcomes compared to baseline status, and blinded saline control injections and at-home exercise therapy (p<0.05). However, long term effects of prolotherapy for knee OA are unknown. We therefore assessed long-term effects of prolotherapy on knee pain, function and stiffness among adults with knee OA. DESIGN: Post clinical-trial, open-label follow-up study. SETTING:Outpatient; adults with mild-to-severe knee OA completing a 52-week prolotherapy study were enrolled. INTERVENTION AND OUTCOME MEASURES: Participants received 3-5 monthly interventions and were assessed using the validated Western Ontario McMaster University Osteoarthritis Index, (WOMAC, 0-100 points), at baseline, 12, 26, 52 weeks, and 2.5 years. RESULTS: 65 participants (58±7.4 years old, 38 female) received 4.6±0.69 injection sessions in the initial 17-week treatment period. They reported progressive improvement in WOMAC scores at all time points in excess of minimal clinical important improvement benchmarks during the initial 52-week study period, from 13.8±17.4 points (23.6%) at 12 weeks, to 20.9±2.8 points, (p<0.05; 35.8% improvement) at 2.5±0.6 years (range 1.6-3.5 years) in the current follow-up analysis. Among assessed covariates, none were predictive of improvement in the WOMAC score. CONCLUSIONS: Prolotherapy resulted in safe, significant, progressive improvement of knee pain, function and stiffness scores among most participants through a mean follow-up of 2.5 years and may be an appropriate therapy for patients with knee OA refractory to other conservative care.
Authors: Jun Wang; Jie Liang; Jin Yao; Hai Xin Song; Xiao Tian Yang; Fang Chao Wu; Ye Ye; Jian Hua Li; Tao Wu Journal: Aging Clin Exp Res Date: 2021-08-27 Impact factor: 3.636
Authors: David Rabago; Laura van Leuven; Lane Benes; Luke Fortney; Andrew Slattengren; Jessica Grettie; Marlon Mundt Journal: J Altern Complement Med Date: 2016-09-07 Impact factor: 2.579
Authors: Regina Ws Sit; Vincent Ch Chung; Kenneth D Reeves; David Rabago; Keith Kw Chan; Dicken Cc Chan; Xinyin Wu; Robin St Ho; Samuel Ys Wong Journal: Sci Rep Date: 2016-05-05 Impact factor: 4.379
Authors: Ross A Hauser; Johanna B Lackner; Danielle Steilen-Matias; David K Harris Journal: Clin Med Insights Arthritis Musculoskelet Disord Date: 2016-07-07